Strength Training Response of Muscle in GLP-1 Users (STRONG-GLP)

Virginia Polytechnic Institute and State University

Status: Enrolling

Conditions: Muscle Mass

Treatments: Other: Wait first, then strength training; Behavioral: Strength Training

Study type: Interventional

Funder types: Other

Identifiers

NCT07104539

25-707

Details and patient eligibility

About

GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.

Enrollment: 30 estimated patients

Sex: All

Ages: 50+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age, 50y+
• Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less
• Weight <300 lb
• Pass a health and exercise readiness screening

Exclusion criteria

• Age <50
• Weight >300 lb
• Osteoporosis
• Active metabolic, neoplastic, or cardiovascular disease
• Unable or unwilling to provide consent

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

30 participants in 2 patient groups

Strenth Training

Experimental group

Description:

Participants will undergo strength training 3 times per week for 14 weeks.

Treatment:

Behavioral: Strength Training

Waitlisted control

Other group

Description:

Participants will have no strength training intervention for 14 weeks. Participants will be offered the same 14-week strength training program after the initial 14 weeks.

Treatment:

Other: Wait first, then strength training